ReviewF1000Research2020
Recent advances in treating oesophageal cancer.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05831150 (Investigating Factors Affecting Clinical Trial Participation Rates in Patients With Esophageal Cancer), which is not on this map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating Factors Affecting Clinical Trial Participation Rates in Patients With Esophageal Cancer
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Anastomotic Leak and Perioperative Outcomes of Esophagectomy for Esophageal Cancer during the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Trial
- LMNTD2-AS1 promotes esophageal squamous cell carcinoma progression by sponging miR-449b-5p to upregulate MYCN.World journal of surgical oncology · 2026Article
- Basal cell subsets, as biomarker to predict the therapeutic effect of neoadjuvant therapy for esophageal carcinoma.Journal of cancer research and clinical oncology · 2026Article
- Article
- IL-11-IL6ST-STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes.Scientific reports · 2026Article
- Development and validation of a nomogram using transaminase levels, cycle cost, and hair loss as predictive factors for the response to neoadjuvant chemotherapy in esophageal cancer.Journal of cardiothoracic surgery · 2026Article
- Elbasvir triggers ferroptosis in esophageal squamous cell carcinoma through NCOA4-mediated ferritinophagy.Medical oncology (Northwood, London, England) · 2026Article
- Article
- Role of histone acetylation in the regulation of CD36 and ANGPTL1 in esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Network analysis of multidimensional symptom experience among postoperative esophageal cancer survivors.Health and quality of life outcomes · 2025Article
- Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma.Genes & genomics · 2025Article
- Correlation of nutritional support and immunonutritional indicators with prognosis and survival in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.Nutrition journal · 2025Article
- Application of total thoracoscopic ultrasonic scalpel resection in esophageal cancer patients.World journal of gastrointestinal surgery · 2025Article
- Anastomotic leakage following robot-assisted minimally invasive esophagectomy (RAMIE): which anastomosis should be preferred?Surgical endoscopy · 2025Observational
- ALDH18A1 has carcinogenic functions and regulates alternative splicing events of DNA repair-related genes in esophageal carcinoma cells.Scientific reports · 2025Article
- Antioxidants Acteoside and Orientin as Emerging Agents in Synergistic Cancer Therapy: A Focus on Innovative Applications.Antioxidants (Basel, Switzerland) · 2025Review
- Basal-like subtype of esophageal adenocarcinoma and it's morphological, molecular and clinical characteristics.Scientific reports · 2025Article
- Progress in the Application of Single-Cell Sequencing in Neoadjuvant Therapy for Esophageal Cancer.Cureus · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a poor prognosis. EC is histologically divided into two major categories: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). EAC and ESCC are molecularly different and therefore treatments should reflect the respective histological subtype. Combined modality therapy is needed for localized EC. When EC is advanced (stage 4), systemic therapy is the mainstay treatment for palliation. For localized EC, several strategies are considered standard, and more trials are necessary to determine a unified and more effective approach. The management for advanced EC is slowly evolving as immunotherapy is showing some promise for ESCC, but more data from ongoing studies are anticipated. Treatment advances will be based on high-definition genomic investigation of individual tumors. Herein, we review the contemporary trends in diagnosing and treating EAC and ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.